1178 related articles for article (PubMed ID: 28783722)
1. Identification of essential genes for cancer immunotherapy.
Patel SJ; Sanjana NE; Kishton RJ; Eidizadeh A; Vodnala SK; Cam M; Gartner JJ; Jia L; Steinberg SM; Yamamoto TN; Merchant AS; Mehta GU; Chichura A; Shalem O; Tran E; Eil R; Sukumar M; Guijarro EP; Day CP; Robbins P; Feldman S; Merlino G; Zhang F; Restifo NP
Nature; 2017 Aug; 548(7669):537-542. PubMed ID: 28783722
[TBL] [Abstract][Full Text] [Related]
2. Natural Killer Cells Suppress T Cell-Associated Tumor Immune Evasion.
Freeman AJ; Vervoort SJ; Ramsbottom KM; Kelly MJ; Michie J; Pijpers L; Johnstone RW; Kearney CJ; Oliaro J
Cell Rep; 2019 Sep; 28(11):2784-2794.e5. PubMed ID: 31509742
[TBL] [Abstract][Full Text] [Related]
3. Acquired IFNγ resistance impairs anti-tumor immunity and gives rise to T-cell-resistant melanoma lesions.
Sucker A; Zhao F; Pieper N; Heeke C; Maltaner R; Stadtler N; Real B; Bielefeld N; Howe S; Weide B; Gutzmer R; Utikal J; Loquai C; Gogas H; Klein-Hitpass L; Zeschnigk M; Westendorf AM; Trilling M; Horn S; Schilling B; Schadendorf D; Griewank KG; Paschen A
Nat Commun; 2017 May; 8():15440. PubMed ID: 28561041
[TBL] [Abstract][Full Text] [Related]
4. Genome-Wide CRISPR Screening Identifies JAK1 Deficiency as a Mechanism of T-Cell Resistance.
Han P; Dai Q; Fan L; Lin H; Zhang X; Li F; Yang X
Front Immunol; 2019; 10():251. PubMed ID: 30837996
[TBL] [Abstract][Full Text] [Related]
5. CD8
Wang W; Green M; Choi JE; Gijón M; Kennedy PD; Johnson JK; Liao P; Lang X; Kryczek I; Sell A; Xia H; Zhou J; Li G; Li J; Li W; Wei S; Vatan L; Zhang H; Szeliga W; Gu W; Liu R; Lawrence TS; Lamb C; Tanno Y; Cieslik M; Stone E; Georgiou G; Chan TA; Chinnaiyan A; Zou W
Nature; 2019 May; 569(7755):270-274. PubMed ID: 31043744
[TBL] [Abstract][Full Text] [Related]
6. USP22 deficiency in melanoma mediates resistance to T cells through IFNγ-JAK1-STAT1 signal axis.
Li M; Xu Y; Liang J; Lin H; Qi X; Li F; Han P; Gao Y; Yang X
Mol Ther; 2021 Jun; 29(6):2108-2120. PubMed ID: 33601053
[TBL] [Abstract][Full Text] [Related]
7. Mutation patterns in genes encoding interferon signaling and antigen presentation: A pan-cancer survey with implications for the use of immune checkpoint inhibitors.
Budczies J; Bockmayr M; Klauschen F; Endris V; Fröhling S; Schirmacher P; Denkert C; Stenzinger A
Genes Chromosomes Cancer; 2017 Aug; 56(8):651-659. PubMed ID: 28466543
[TBL] [Abstract][Full Text] [Related]
8. Local Delivery of OncoVEX
Moesta AK; Cooke K; Piasecki J; Mitchell P; Rottman JB; Fitzgerald K; Zhan J; Yang B; Le T; Belmontes B; Ikotun OF; Merriam K; Glaus C; Ganley K; Cordover DH; Boden AM; Ponce R; Beers C; Beltran PJ
Clin Cancer Res; 2017 Oct; 23(20):6190-6202. PubMed ID: 28706012
[No Abstract] [Full Text] [Related]
9. Targeting REGNASE-1 programs long-lived effector T cells for cancer therapy.
Wei J; Long L; Zheng W; Dhungana Y; Lim SA; Guy C; Wang Y; Wang YD; Qian C; Xu B; Kc A; Saravia J; Huang H; Yu J; Doench JG; Geiger TL; Chi H
Nature; 2019 Dec; 576(7787):471-476. PubMed ID: 31827283
[TBL] [Abstract][Full Text] [Related]
10. Pooled in vivo screens for cancer immunotherapy target discovery.
Lane-Reticker SK; Manguso RT; Haining WN
Immunotherapy; 2018 Mar; 10(3):167-170. PubMed ID: 29370725
[No Abstract] [Full Text] [Related]
11. CD8
Farhood B; Najafi M; Mortezaee K
J Cell Physiol; 2019 Jun; 234(6):8509-8521. PubMed ID: 30520029
[TBL] [Abstract][Full Text] [Related]
12. Increased antitumor efficacy of PD-1-deficient melanoma-specific human lymphocytes.
Marotte L; Simon S; Vignard V; Dupre E; Gantier M; Cruard J; Alberge JB; Hussong M; Deleine C; Heslan JM; Shaffer J; Beauvais T; Gaschet J; Scotet E; Fradin D; Jarry A; Nguyen T; Labarriere N
J Immunother Cancer; 2020 Jan; 8(1):. PubMed ID: 32001504
[TBL] [Abstract][Full Text] [Related]
13. Acquired Immune Resistance Follows Complete Tumor Regression without Loss of Target Antigens or IFNγ Signaling.
Donia M; Harbst K; van Buuren M; Kvistborg P; Lindberg MF; Andersen R; Idorn M; Munir Ahmad S; Ellebæk E; Mueller A; Fagone P; Nicoletti F; Libra M; Lauss M; Hadrup SR; Schmidt H; Andersen MH; Thor Straten P; Nilsson JA; Schumacher TN; Seliger B; Jönsson G; Svane IM
Cancer Res; 2017 Sep; 77(17):4562-4566. PubMed ID: 28655789
[TBL] [Abstract][Full Text] [Related]
14. Human effector T cells derived from central memory cells rather than CD8(+)T cells modified by tumor-specific TCR gene transfer possess superior traits for adoptive immunotherapy.
Wu F; Zhang W; Shao H; Bo H; Shen H; Li J; Liu Y; Wang T; Ma W; Huang S
Cancer Lett; 2013 Oct; 339(2):195-207. PubMed ID: 23791878
[TBL] [Abstract][Full Text] [Related]
15. Topical treatment of all-trans retinoic acid inhibits murine melanoma partly by promoting CD8
Yin W; Song Y; Liu Q; Wu Y; He R
Immunology; 2017 Oct; 152(2):287-297. PubMed ID: 28556970
[TBL] [Abstract][Full Text] [Related]
16. Multiple structural and epigenetic defects in the human leukocyte antigen class I antigen presentation pathway in a recurrent metastatic melanoma following immunotherapy.
Chang CC; Pirozzi G; Wen SH; Chung IH; Chiu BL; Errico S; Luongo M; Lombardi ML; Ferrone S
J Biol Chem; 2015 Oct; 290(44):26562-75. PubMed ID: 26381407
[TBL] [Abstract][Full Text] [Related]
17. In vivo CRISPR screening identifies Ptpn2 as a cancer immunotherapy target.
Manguso RT; Pope HW; Zimmer MD; Brown FD; Yates KB; Miller BC; Collins NB; Bi K; LaFleur MW; Juneja VR; Weiss SA; Lo J; Fisher DE; Miao D; Van Allen E; Root DE; Sharpe AH; Doench JG; Haining WN
Nature; 2017 Jul; 547(7664):413-418. PubMed ID: 28723893
[TBL] [Abstract][Full Text] [Related]
18. In vitro induction of tumor-specific human lymphocyte antigen class I-restricted CD8 cytotoxic T lymphocytes by ovarian tumor antigen-pulsed autologous dendritic cells from patients with advanced ovarian cancer.
Santin AD; Hermonat PL; Ravaggi A; Bellone S; Pecorelli S; Cannon MJ; Parham GP
Am J Obstet Gynecol; 2000 Sep; 183(3):601-9. PubMed ID: 10992180
[TBL] [Abstract][Full Text] [Related]
19. Recent Advances in Lung Cancer Immunotherapy: Input of T-Cell Epitopes Associated With Impaired Peptide Processing.
Leclerc M; Mezquita L; Guillebot De Nerville G; Tihy I; Malenica I; Chouaib S; Mami-Chouaib F
Front Immunol; 2019; 10():1505. PubMed ID: 31333652
[TBL] [Abstract][Full Text] [Related]
20. Loss of ADAR1 in tumours overcomes resistance to immune checkpoint blockade.
Ishizuka JJ; Manguso RT; Cheruiyot CK; Bi K; Panda A; Iracheta-Vellve A; Miller BC; Du PP; Yates KB; Dubrot J; Buchumenski I; Comstock DE; Brown FD; Ayer A; Kohnle IC; Pope HW; Zimmer MD; Sen DR; Lane-Reticker SK; Robitschek EJ; Griffin GK; Collins NB; Long AH; Doench JG; Kozono D; Levanon EY; Haining WN
Nature; 2019 Jan; 565(7737):43-48. PubMed ID: 30559380
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]